The association of 5α-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population

DNA and Cell Biology

Volumn 26, Issue 2, 2007, Pages 100-107

  Onen, Ilke Hacer ^a   Ekmekci, Abdullah ^a   Eroglu, Muzaffer ^b   Polat, Fazli ^a   Biri, Hasan ^a  

^a GAZI UNIVERSITY   (Turkey)

^b ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; STEROID 17ALPHA MONOOXYGENASE; STEROID 5ALPHA REDUCTASE;

ADULT; AGED; ARTICLE; CANCER GENETICS; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CODON; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYP17 GENE; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POPULATION RISK; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SRD5A2 GENE; TURKEY (REPUBLIC); GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE; TESTOSTERONE 5-ALPHA-REDUCTASE; TURKEY;

EID: 33847690738     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2006.0534     Document Type: Article

References (35)

1. ANTOGNELLI, C., MEARINI, L., TALESA, V.N., GIANNANTONI, A., and MEARINI, E. (2005). Association of CYP17, GSTPI and PONI polymorphisms with the risk of prostate cancer. Prostate 63, 240-251.
2. BJELFMAN, C., SODERSTROM, T.G., BREKKAN, E., NORLEN, B.J., EGEVAD, L., UNGE, T., ANDERSSON, S., and RANE, A. (1997). Differential gene expression of steroid 5 alpha-reductase 2 in core needle biopsies from malignant and benign prostatic tissue. J. Clin. Endocrinol. Metab. 82, 2210-2214.
3. CHANG, B., ZHENG, S.L., ISAACS, S.D., WILEY, K.E., CARPTEN, J.D., HAWKINS, G.A., BLEECKER, E.R., WALSH, P.C., TRENT, J.M., MEYERS, D.A., et al. (2001). Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. Int. J. Cancer 95, 354-359.
4. FEBBO, P.G., KANTOFF, P.W., PLATZ, E.A., CASEY, D., BATTER, S., GIOVANNUCCI, E., HENNEKENS, C.H., and STAMPFER, M.J. (1999). The V89L polymorphism in the 5 α-reductase type 2 gene and risk of prostate cancer. Cancer Res. 59, 5878-5881.
5. GIWERCMAN, Y.L., ABRAHAMSSON, P.A., GIWERCMAN, A., GADALEANU, V., and AHLGREN, G. (2005). The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population. Eur. Urol. 48, 679-685.
6. GSUR, A., BERNHOFER, G., HINTEREGGER, S., HAIDINGER, G., SCHATZL, G., MADERSBACHER, S., MARBERGER, M., VUTUC, C., and MICKSCHE, M. (2000). A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int. J. Cancer 87, 434-437.
7. HABUCHI, T., LIQING, Z., SUZUKI, T., SASAKI, R., TSUCHIYA, N., TACHIKI, H., SHIMODA, N., SATOH, S., SATO, K., KAKEHI, Y., et al. (2000). Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res. 15, 5710-5713.
8. HAIMAN, C.A., STAMPFER, M.J., GIOVANNUCCI, E., MA, J., DECALO, N.E., KANTOFF, P.W., and HUNTER, D.J. (2001). The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol. Biomarkers Prev. 10, 743-748.
9. HSING, A.W., CHEN, C., CHOKKALINGAM, A.P., GAO, Y.T., DIGHTMAN, D.A., NGUYEN, H.T., DENG, J., CHENG, J., SESTERHENN, I.A., MOSTOFI, F.K., et al. (2001). Polymorphic markers in the SRD5A2 gene and prostate cancer risk: A population-based case-control study. Cancer Epidemiol. Biomarkers Prev. 10, 1077-1082.
10. JAFFE, J.M., MALKOWICZ, S.B., WALKER, A.H., MACBRIDE, S., PESCHEL, R., TOMASZEWSKI, J., VAN ARSDALEN, K., WEIN, A.J., and REBBECK, T.R. (2000). Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res. 60, 1626-1630.
11. JEMAL, A., MURRAY, T., SAMUELS, A., GHAFOOR, A., WARD, E., and THUN, M.J. (2003). Cancer statistics. CA Cancer J. Clin. 53, 5-26.
12. KITTLES, R.A., PANGULURI, R.K., CHEN, W., MASSAC, A., AHAGHOTU, C., JACKSON, A., UKOLI, F., ADAMS-CAMPBELL, L., ISAACS, W., and DUNSTON, G.M. (2001). CYP17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol. Biomarkers Prev. 10, 943-947.
13. LATIL, A.G., AZZOUZI, R., CANCEL, G.S., GUILLAUME, E.C., COCHAN-PRIOLLET, B., BERTHON, P.L., and CUSSENOT, O. (2001). Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 92, 1130-1137.
14. LI, Z., HABUCHI, T., MITSUMORI, K., KAMOTO, T., KINOSHITU, H., SEGAWA, T., OGAWA, O., and KATO, T. (2003). Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. J. Urol. 169, 2378-2381.
15. LUNN, R.M., BELL, D.A., MOHLER, J.L., and TAYLOR, J.A. (1999). Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 20, 1727-1731.
16. MADIGAN, M.P., GAO, Y.T., DENG, J., PFEIFFER, R.M., CHANG, B.L., ZHENG, S., MEYERS, D.A., STANCZYK, F.Z., XU, J., and HSING, A.W. (2003). CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: A population-based study in China. Int. J. Cancer 107, 271-275.
17. MAKRIDAKIS, N., ROSS, R.K., PIKE, M.C., CHANG, L., STANCZYK, F.Z., KOLONEL, L.N., SHI, C.Y., YU, M.C., HENDERSON, B.E., and REICHARDT, J.K. (1997). A prevalent missense substitution that modulates activity of prostatic steroid 5 α-reductase. Cancer Res. 57, 1020-1022.
18. MAKRIDAKIS, N.M., ROSS, R.K., PIKE, M.C., CROCITTO, L.E., KOLONEL, L.N., PEARCE, C.L., HENDERSON, B.E., and REICHARDT, J.K. (1999). Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354, 975-978.
19. MAKRIDAKIS, N.M., SALLE, E., and REICHARDT, K.V.J. (2000). Biochemical and pharmacogenetic dissection of human steroid 5 α-reductase type II. Pharmacogenetics 10, 407-413.
20. MEHRIAN-SHAI, R., and REICHARDT, J.K. (2004). A renaissance of "biochemical genetics"? SNPs, haplotypes, function, and complex disease. Mol. Genet. Metab. 83, 47-50.
21. MONONEN, N., IKONEN, T., SYRJAKOSKI, K., MATIKAINEN, M., SCHLEUTKER, J., TAMMELA, T.L., KOIVISTO, P.A., and KALLIONIEMI, O.P. (2001). A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Br. J. Cancer 84, 1344-1347.
22. NAM, R.K., TOI, A., VESPRINI, D., HO, M., CHU, W., HARVIE, S., SWEET, J., TRACHTENBERG, J., JEWETT, M.A., and NAROD, S.A. (2001). V89L polymorphism of type-2,5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology 57, 199-205.
23. NAUCK, M., MARZ, W., and WIELAND, H. (2002). Rapid detection of missense mutations in the ptostatic steroid 5α-reductase gene using real-time fluorescence PCR and melting curve analysis. In Rapid Cycle Real-Time PCR, Methods and Applications: Genetics and Oncology. W. Dietmaier; N. Wittwer, and N. Sivasubramanian, eds. (Springer-Verlag Berlin and Heidelberg GmbH & Co., Germany) pp. 129-135.
24. NTAIS, C., POLYCARPOU, A., and IOANNIDIS, J.P. (2003a). Association of the CYP17 gene polymorphism with the risk of prostate cancer: A meta-analysis. Cancer Epidemiol. Biomarkers Prev. 12, 120-126.
25. NTAIS, C., POLYCARPOU, A., and IOANNIDIS, J.P.A. (2003b). SRD5A2 gene polymorphisms and the risk of prostate cancer: A meta-analysis. Cancer Epidemiol. Biomarkers Prev. 12, 618-624.
26. NWOSU, V., CARPTEN, J., TRENT, J.M., and SHERIDAN, R. (2001). Heterogeneity of genetic alterations in prostate cancer: Evidence of the complex nature of the disease. Hum. Mol. Genet. 10, 2313-2318.
27. SALAM, M.T., URSIN, G., SKINNER, E.C., DESSISSA, T., and REICHARDT, J.K. (2005). Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol. Oncol. 23, 246-253.
28. SCHATZL, G., MADERSBACHER, S., GSUR, A., PREYER, M., HAIDINGER, G., HAITEL, A., VUTUC, C., MICKSCHE, M., and MARBERGER, M. (2002). Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. Prostate 52, 130-138.
29. SOBTI, R.C., ONSORY, K., AL-BADRAN, A.I., KAUR, P., WATANABE, M., KRISHAN, A., and MOHAN, H. (2006). CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biol. 25, 287-294.
30. SODERSTROM, T., WADELIUS, M., ANDERSSON, S.O., JOHANSSON, I.E., JOHANSSON, S., GRANATH, P., and RANE, A. (2002). 5 α-Reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 12, 307-312.
31. THOMPSON, I.M., GOODMAN, P.J., TANGEN, C.M., LUCIA, M.S., MILLER, G.J., FORD, L.G., LIEBER, M.M., CESPEDES, R.D., ATKINS, J.N., LIPPMAN, S.M., et al. (2003). The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215-224.
32. TIGLI, H., YAZICI, H., and DALAY, N. (2003). Cyp17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia. Res. Commun. Mol. Pathol. Pharmacol. 113-114, 307-314.
33. WADELIUS, M., ANDERSSON, A.O., JOHANSSON, J.E., WADELIUS, C., and RANE, E. (1999). Prostate cancer associated with CYP17 genotype. Pharmacogenetics 9, 635-639.
34. YAMADA, Y., WATANABE, M., MURATA, M., YAMANAKA, M., KUBOTA, Y., ITO, H., KATOH, T., KAWAMURA, J., YATANI, R., and SHIRAISHI, T. (2001). Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int. J. Cancer 92, 683-686.
35. ZEIGLER-JOHNSON, C.M., WALKER, A.H., MANCKE, B., SPANGLER, E., JALLOH, M., MCBRIDE, S., DEITZ, A., MALKOWICZ, S.B., OFORI-ADJEI, D., GUEYE, S.M., et al. (2002). Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum. Hered. 54, 13-21.